Streetbeat News

Earnings

GXAI

VJET

WSM

U.S. stocks traded mixed with the Nasdaq Composite down and the Dow up. Williams-Sonoma reported better-than-expected earnings and announced a new $1 billion stock repurchase and dividend increase. Gaxos.ai surged after acquiring AI technology rights, while voxeljet announced a voluntary Nasdaq delisting. Energy shares led gains, while information technology shares lagged.

Portfolio Pulse from Avi Kapoor

March 13, 2024 | 1:49 pm

FCX

Whales have shown a bearish stance on Freeport-McMoRan (FCX), with 69% of detected trades being bearish. The trading activity suggests a price target range between $30.0 and $42.5. Notable options activity includes both bullish and bearish sentiments, with a current stock price of $41.57 and a neutral RSI. The company's earnings release is anticipated in 37 days.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 1:46 pm

UAVS

AgEagle Aerial Systems Inc. (NYSE:UAVS), a leading drone solutions provider, announced a shareholder letter from Chairman Grant Begley, highlighting the company's evolution, product offerings, and strategic accomplishments. Begley emphasized AgEagle's transition from a local agricultural drone provider to a global leader in drone technology with applications across various sectors. The letter mentioned the introduction of eBee VISION for defense and security, FAA certification, and the Defense Innovation Unit's endorsement. Recent achievements include leadership team expansions, sales to UT-Battelle and ADS Inc., and recognition as a top AI company in agriculture. Financially, AgEagle addressed its micro cap status, sales stagnation, and high expenses in 2023, but anticipates growth with the eBee VISION. A 20-to-1 reverse stock split was approved to attract more investors and support business growth.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 1:43 pm

SLGL

Sol-Gel Technologies (NASDAQ:SLGL) reported Q4 earnings with an EPS of $-0.17, matching estimates, and a revenue increase of $347 thousand from the previous year. Despite meeting EPS estimates, past performance shows a 7% drop in share price following last quarter's earnings beat.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 1:40 pm

INDP

Indaptus Therapeutics (NASDAQ:INDP) reported Q4 earnings, beating estimates with an EPS of $-0.46 against an expected $-0.54. However, revenue remained unchanged from the previous year. Despite beating last quarter's EPS estimates, the share price dropped by 10% the following day.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 1:40 pm

CLNN

Clene (NASDAQ:CLNN) reported Q4 earnings with an EPS of $-0.01, beating estimates by 86.0% against an expected $-0.07. However, revenue decreased by $64 thousand compared to the same period last year. In the previous quarter, Clene also surpassed EPS estimates, which was followed by a 1.0% drop in share price the next day.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 1:40 pm

GAN

GAN (NASDAQ:GAN) reported Q4 earnings with a significant miss on estimated earnings by -40.0%, posting an EPS of $-0.21 against an estimate of $-0.15. Revenue also saw a decrease of $6.23 million from the same period last year. This follows a pattern of fluctuating performance in previous quarters, with the last quarter showing a beat on EPS estimates but no subsequent increase in share price.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 1:35 pm

TRDA

Entrada Therapeutics (NASDAQ:TRDA) reported Q4 earnings with a significant miss on estimated earnings by -71.0%, posting an EPS of $-0.29 against an estimate of $-0.17. However, revenue saw an increase of $41.85 million from the same period last year. Despite beating EPS estimates last quarter, the share price dropped by 1.0% the following day.

Portfolio Pulse from Benzinga Insights

March 13, 2024 | 1:35 pm

DG

Dollar General Corp (NYSE:DG) is set to report its Q4 earnings on March 14, with Wall Street expecting $1.75 EPS and $9.78 billion in revenues. The stock has seen a significant recovery, up 55% since Oct. 2, 2023, and about 19% in 2024 so far. A Golden Cross is about to be triggered, indicating a bullish trend reversal. Analyst consensus rates the stock as Neutral with a price target of $134.07, though recent reviews suggest a target of $155-$158. The stock closed at $161.22 on March 12.

Portfolio Pulse from Surbhi Jain

March 13, 2024 | 1:30 pm

ARQ

Arq shares are trading higher following the announcement of their Q4 financial results, which exceeded expectations.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 1:28 pm